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Abstract: Innate immune interferons (IFNs), including type I and III IFNs, constitute critical antiviral
mechanisms. Recent studies reveal that IFN dysregulation is key to determine COVID-19 pathogenesis.
Effective IFN stimulation or prophylactic administration of IFNs at the early stage prior to severe
COVID-19 may elicit an autonomous antiviral state, restrict the virus infection, and prevent COVID-19
progression. Inborn genetic flaws and autoreactive antibodies that block IFN response have been
significantly associated with about 14% of patients with life-threatening COVID-19 pneumonia.
In most severe COVID-19 patients without genetic errors in IFN-relevant gene loci, IFN dysregulation
is progressively worsened and associated with the situation of pro-inflammation and immunopathy,
which is prone to autoimmunity. In addition, the high correlation of severe COVID-19 with seniority,
males, and individuals with pre-existing comorbidities will be plausibly explained by the coincidence
of IFN aberrance in these situations. Collectively, current studies call for a better understanding
of the IFN response regarding the spatiotemporal determination and subtype-specificity against
SARS-CoV-2 infections, which are warranted to devise IFN-related prophylactics and therapies.
Keywords: COVID-19; interferons; interferon signaling; SARS-CoV-2; immunopathy
1. Diverted Type I Interferon (IFN) Response Associated with Hyper-Inflammation
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the current
pandemic of new coronavirus disease 2019 (COVID-19), shows an evolutionary success to adapt
its infectivity and contagiousness to efficiently spread in human societies [1–6]. The prognosis of
SARS-CoV-2-infected patients is very broad, with a vast majority of people (50–80% based on different
research scenarios, CDC) only having mild symptoms like the common cold or asymptomatic [7];
however, still, the other significant numbers (averagely 20–50% based on different ethnicity and
pre-medical conditions) may progress into severe respiratory and systemic syndromes, needing
immediate hospitalization and critical care [8–12]. The case fatality rate of COVID-19 ranges from
1.7–13.0% in different countries [7]. Except for the pathogenic impact of viral infection, major pathologies
underlying severe COVID-19 come from the dysregulation of vast immune factors at both the cellular
and molecular levels. For example, severe COVID-19 patients display macrophage overreaction
(also known as macrophage activation syndrome (MAS)) and lymphopenias of effective lymphocytes,
including neutrophils, CD4 T cells, and natural killer (NK) cells [13–15]. At the molecular level,
hyper-regulation of pro-inflammatory mediators (including IL-6, TNFα, S100A8/9, and C-reactive
protein), a significant decrease of human leukocyte antigen D-related (HLA-DR) gene expression in
CD14 monocytes, and dysregulated antiviral interferon (IFN) response have been reported in COVID-19
patients with critical illness [13–15]. In this review, we focus on the determinant role of dysfunctional
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IFN response underlying the progression of severe COVID-19. Interferon (IFN) system comprises
a series of antiviral IFN cytokines, classified as type I, II, and III based on their distinct molecular
signatures and recognition receptors in cells, to induce hundreds of IFN-stimulated effector genes
(ISGs), exerting various antiviral and other immunomodulatory functions (Figure 1) [16–18]. The IFN
molecules of three IFN types are further designated into subtypes, which include the single IFN-γ
for type II and IFN-λ1-4 for type III, such as in humans. There are multiple subtypes of type I IFNs,
which include general subtypes of IFN-α and IFN-β produced by most cells, and more cell-specific
subtypes, including IFN-ε (reproductive tract), IFN-κ (keratinocytes), IFN-ω (leukocytes/epithelial
cells), and species-specific subtypes of IFN-δ (pigs), IFN-τ (cattle), and IFN-ξ (mice) [16–18].
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mechanisms against the host IFN signaling and especially those on early IFN induction signaling. 
Note, cellular IFN induction may go with either a MAVS- or STING-dependent pathways that 
respond to cytosolic pathogenic RNA or DNA molecular patterns, respectively. Similarly, IFN action 
signaling may lead through a canonical ISGs induction with limited pro-inflammation or crosstalk 
with inflammatory signaling from TNF and TLR to increase the expression of non-canonical ISGs 
accompanying a pro-inflammatory and autoimmune ambient through epigenetic regulation. The 
canonical IFN signaling flow, which acts generally at an early stage of SARS-CoV-2 infection for 
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associated with pro-inflammation and immunopathies.  
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Figure 1. SAR -CoV-2 genomic structure and a l ical antagonism to int rferon (IFN) signaling.
Analogical to typical human β-cor naviruses, the S enome contains ORF1a/1b, encoding a
polyprotein, wh ch is proteolytically processed into no -structural protein (Nsp) 1–16 (top schematic).
Structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins,
are diagramed to depict the genome and viron structures (middle). Other accessory proteins encoded
at the 3′ end of the viral genome comprise ORF3a, 3b, 6, 7a, 7b, 8, 9a, 9b, and 10 (colored in grey).
The bottom panel depicts SARS-CoV-2 proteins (colored ovals with red outlines) that interfere with
either IFN induction or action pathways and are posited next to their known or hypothetic targets/steps
in the IFN signaling. SARS-CoV-2 seems to evolve multiple antagonistic mechanisms against the host
IFN signaling and especially those on early IFN induction signaling. Note, cellular IFN induction
may go with either a MAVS- or STING-dependent pathways that respond to cytosolic pathogenic
RNA or DNA molecular patterns, respectively. Similarly, IFN action sign ling may lead through a
canonical ISGs induction with limited pro-inflamma io or crosstalk with inflammatory signaling from
TNF nd TLR to increase the expression of non-cano ical ISGs accompanying a pro-infl mmatory and
autoimmune ambient through epigenetic regulation. The canonical IFN signaling flow, which acts
generally at an early stage of SARS-CoV-2 infection for primarily restricting viral infection, is depicted
using black arrows, and brown arrows represent the non-canonical IFN signaling flow activated at a
later stage in severe COVID-19, which is highly associated with pro-inflammation and immunopathies.
Studies using transcriptomic analysis in SARS-CoV2-infected human bronchial cells or IFN
assays in clinical plasma samples demonstrated a distinct immune-reaction phenotype in symptomatic
COVID-19 patients, being a highly impaired interferon (IFN) response [19,20]. The impaired type I IFN
response was characterized by decreased IFN-α/β expression in both SARS-CoV-2-infected human
bronchial cells and circulating mononuclear blood cells, which was diagnosed together with persistent
viremia and an exacerbated inflammatory response upon reactions to increased pro-inflammatory
mediators, including tumor necrosis factor–α (TNF-α) and interleukin (IL)-6 [19,20]. Together with other
previous in vitro studies, these data suggest that SARS-CoV-2 bears similar antagonistic mechanisms
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as other severe human coronaviruses (i.e., SARS and MERS) to interfere with the host IFN signaling,
especially the production of type I IFNs (Figure 1) [21,22]. In contrast, other studies by Lee et al.
(2020) and Lucas et al. (2020) detected that patients with severe COVID-19 had a sustained type I
IFN response and consistent pro-inflammatory response in the blood of patients subjected to severe
COVID-19 [23,24]. Contradictory results about type I IFN responses in COVID-19 patients may come
from the disparity of criteria to define disease severity and different sampling times during the disease
progression [25]. In addition, using large cohorts of COVID-19 patients in European countries, recent
genome-wide association studies (GWAS) have significantly associated several critical genetic loci
with severe COVID-19, which contain genetic regions spanning multiple genes that are centered
in both chemokine and IFN signaling [26,27]. All these studies highlight the potential role of IFN
signaling in determining the host susceptibility to SARS-CoV-2 infection and the progression of severe
COVID-19 [19–27].
Interferon signaling, for either IFN induction or action, is not a linear cascade but an
interacting network, dynamically adapting to alternative and crosstalk with other cytokine signaling
pathways [16–18,25,27]. For IFN induction signaling during an RNA-virus infection as in COVID-19,
the typical pathway is triggered by viral RNA through membrane-bound or cytoplasmic receptors
(TLRs or RLR, as in Figure 1) and culminated at IFN-regulatory factor (IRF)-3/7 activation and IFN
expression. Alternatively, animal cells are also capable of inducing IFN expression through cellular
receptor-like cyclic GMP-AMP synthase (cGAS) to detect pathogenic DNA (pDNA) motifs from bacteria,
viruses, and dead cells and to activate a stimulator of IFN genes (STING)-dependent pathway for IFN
and inflammatory cytokine production (Figure 1, bottom-left panel). Similarly, for IFN action signaling,
the canonical IFN signaling is through the engagement of membrane-bound IFN receptor (Figure 1,
IFNA/LR for type I and III IFNs, respectively) and activation of STAT1/2 and ISGF3 transcription factors,
leading to robust expression of hundreds of classical IFN-stimulated genes (ISGs, such as ISG15, MxA,
IFITM, etc.), which exert antiviral role to restrict viral replication and spreading [16–18]. Alternatively,
IFN signaling may divert to or synergize with TLR-mediated or cytokines (mainly TNF) signaling
pathways to epigenetically promote the expression of a group of recently characterized non-canonical
ISGs (non-ISGs) [18,28,29]. Two newly characterized non-canonical ISGs are inflammatory cytokine IL-6
and angiotensin-converting enzyme 2 (ACE2), a key component in the renin-angiotensin-aldosterone
system (RAAS) and adopted by SARS-CoV-2 as a primary cellular receptor for infection [30–32]. For an
RNA-virus infection like in COVID-19, the canonical IFN induction and action signaling are plausibly
activated early to induce IFN and ISG production due to cell perceiving the presence of viral RNA in
infected cells. The non-canonical IFN signaling for that responding to pDNA through cGAS-STING
and non-canonical ISG stimulation via IFN-TNF epigenetic coordination might occur at the later stage,
accompanying massive cell death from pyroptosis (a highly inflammatory form of programmed cell
death in infected cells) and NETosis (an immunologically regulated form of neutrophil cell death),
as seen in severe COVID-19 cases [16–18,33–38]. In addition to induction of IFNs/ISGs, the canonical
and especially non-canonical IFN signaling pathway also lead to the production of inflammatory
cytokines, which is further exacerbated by the virus suppression of ACE2 activity to develop into a
cytokine release syndrome (CRS) or cytokine storm [30,31,34–38]. We propose that the integration of
both canonical and non-canonical IFN signaling sufficiently addresses the contradictory observations
from different studies, as discussed previously [19–25]. It explains that: (1) the weak IFN response is
due to SARS-CoV-2-suppression on the canonical IFN signaling mainly triggered by viral RNA species,
which signifies the early stage of the disease prior to severe progression [19–21]; (2) the robust IFN/ISG
observations in severe COVID-19 cases accumulate consequential activation of non-canonical IFN
signaling through both cGAS-STING for IFN production and IFN-TNF epigenetic regulation for ISG
expression [23,24,33–38], which mostly happen at the late stage of the severe COVID-19 or when patients
experience the complication of progressive pneumonia and multi-organ damage [23,24]. To support
this proposal, the most known IFN antagonistic mechanisms of SARS-like coronavirus evolve to target
major components of IFN canonical signaling, especially for IFN induction (Figure 1) [21]. Intensively,
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a study by Christopher et al. (2020) indicated that the IFN suppression of SARS-CoV-2 (probably
through NSP3 on IRF3) effectively curated inflammatory responses through the cGAS-STING pathway,
correlating to immunopathies from IFN dysregulation, which is worsen in severe COVID-19 [37–39].
2. Immunopathological Effect of Dysregulated IFN Responses
The suppression of IFN response, especially IFN production at the early stage of COVID-19
progression, diminishes the host capacity to restrict (thus benefits) the virus spreading [19,20,40].
Notably, the IFN system, like all other immune mechanisms, can be a double-edged sword to cause
immunopathies, given it is not activated appropriately at the right time or intensity [41–43]. As in
COVID-19, both the early stage of type I IFN deficiency and the late stage of IFN persistence could
be a hallmark of severe COVID-19 [19–24]. As well studied in the cases of major autoimmune
diseases and chronic viral infections, type I IFNs (IFN-α and IFN-β) are widely associated
with immunopathology [33,40–43]. In contrast, type III IFN (IFN-λ) responses are restrictively
mucosa-specific and exert antiviral defense with less damage from pro-inflammatory responses [17,43].
Accordingly, IFN-λ has been thought to have therapeutic advantages in COVID-19 [43]. However,
updated studies in COVID-19 complicate the prophylactic promise of type III IFN-based clinical
trials. Broggi et al. determined the subtype-dependent stimulation of type I and type III IFNs in
the upper airway (naso-oropharyngeal swabs) and lung (BALF) samples and their correlation to
COVID-19 patient morbidity [44]. Data showed that the virus-positive BALF samples from the severe
COVID-19 patients in ICUs contained significant higher human IFN-α/β and type III IFN-λ2/3 but not
IFN-λ1 compared with either the virus-positive or -negative swab samples [45]. Further data from
in vivo mouse models indicate that the inductive expression of IFN-α/β and IFN-λ2/3 by the lung
immune cells (primarily dendritic cells) causes damage to the lung epithelium, which hampers lung
repair and increases susceptibility to lethal bacterial coinfections [44–46]. Indeed, a meta-analysis
evaluated 4.3–9.5% of COVID-19 patients with a bacterial infection, which was more common in
severe patients (8.1%) [47] and so were the incidences of co-infection from other microbes, including
fungi and other viruses, in critically ill COVID-19 patients who suffer dysfunctional IFN and other
immune reactions [48]. As mammalian IFN-α and IFN-λ2/3 subtypes evolve more inductive and
antiviral activity than the epithelial-specific IFN subtypes (such as IFN-β and IFN-λ1) [49,50], the robust
reaction of inflammatory IFN responses via recruited immune cells in the lung certainly deteriorate
the pulmonary homeostasis maintained by the epithelial IFN subtypes, which is more constitutively
expressed by pneumocytes prior to immunopathic IFN responses in severe COVID-19. Therefore,
the more subtype-specific examination of the immunomodulatory and antiviral roles of both type I
and type III IFNs in SARS-CoV-2 infection is imperative for IFN-based prophylactic development [25].
3. Evidence from Life-Threatening COVID-19 Cases with Inborn IFN Deficiency
By genetic screening of 659 patients with life-threatening COVID-19 pneumonia, relative to
534 subjects with asymptomatic or benign infections, Zhang et al. (2020) detected an enrichment in
a functional deficiency of 13 human gene loci that are known to govern TLR3- and IRF7-mediated
antiviral IFN induction signaling in the severe COVID-19 patients [51]. These inborn errors in IFN
induction ascribed to 23 patients (3.5%) who experienced life-threatening COVID-19 and aged 17
to 77 years. Despite a small proportion, the correlation indicated a group of the genetic extremity
(compared with progressive IFN suppression by the virus and potential comorbidity conditions) in
IFN deficiencies, underlying life-threatening COVID-19 patients without prior severe infection [51].
Another study by Bastard et al. (2020) revealed an autoimmune blocking of IFN action signaling [52].
In this case, they detected 101 of 987 (10.2%) patients with life-threatening COVID-19 pneumonia had
auto-antibodies (auto-Abs), which were capable of binding and functionally blocking out almost all
subtypes of type I IFNs, particularly of IFN-α, IFN-ω, and both IFN-α/ω subtypes, in further antiviral
regulation [52]. In a few cases, the auto-antibodies were also detected against the tissue-specific type
I IFN subtypes, including IFN-ε and IFN-κ typically expressed in the reproductive tract and skin
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keratinocytes, respectively [53,54]. In comparison, these auto-Abs were rarely found in the control
cohort (663 individuals) who were SARS-CoV-2-positive but asymptomatic or with mild signs [52].
Comparably, auto-Abs against type I IFNs have been previously reported in patients subjected to
IFN therapies and of systemic lupus erythematosus [55,56] and detected in almost all patients with
autoimmune polyendocrinopathy syndrome type I (APS-1) [52,57]. In addition, 95% of the patients
with the IFN auto-Abs have been male, which may at least partially explain why men face a higher risk
of severe COVID-19, resulting in a higher risk of mortality [10,11,52]. Collectively, evidence from both
inborn deficiency and auto-immune blocking of IFN function elegantly demonstrate that IFN signaling
is a critical determinant of severe COVID-19 progression [51,52].
4. Category of IFN Dysregulation Underlying Severe COVID-19 Development
Figure 2 recaps our understanding of the dynamic interaction of the host IFN system with
SARS-CoV-2 infection and the progression of COVID-19 into a severe status. The majority of healthy
individuals, who are capable of mounting effective IFN responses during the early phase of the
viral infection, will be recovered naturally or without intensive medical care to escape from the
worse progression [58–60]. However, for another proportion of patients, who have pre-existing
comorbidity or concur with a chronic inflammatory condition, their IFN response will be swayed
to an immunopathic situation to exacerbate pneumonia in a severe COVID-19 development [61–63].
Dysregulation of IFNs and other immune factors have been associated with aging, sex difference,
and pre-existing medical conditions, which have been clinically associated with a higher risk of
severe COVID-19 [10–12,61–63]. Studies have shown that the capacity of both blood and lung
dendritic cells (DCs), as a group of major IFN producers, in IFN production is severely impaired
in aged individuals when compared to juveniles. On the contrary, blood DCs from aged people
secrete higher basal levels of pro-inflammatory cytokines/chemokines, including IL-6, TNF-α, CXCL-8,
CXCL-10 [64,65]. Together with other aging-associated lymphocytic abnormalities [66], this IFN and
inflammatory dysregulation in DC response in aged individuals may invoke lung inflammation, impair
antiviral resistance, and exaggerate major clinical signs as exacerbated in severe COVID-19 [8–12].
For the sex difference of IFN response, studies have demonstrated that plasmacytoid DCs (pDC)
from healthy females are more potent to produce type I IFNs via TLR7-mediated signaling than the
pDCs from males [67,68]. Plasmacytoid DCs serve as natural IFN producers and efficient sentinels
in orchestrating antiviral immunity. This finding implicates an inferior status of males in the early
antiviral IFN induction, a suitable stage for most IFN-based clinical trials having positive effects [25].
As for most preexisting medical conditions, including cardiovascular diseases, hypertension, obesity,
and diabetes mellitus, which increase the risk of severe COVID-19 [61,63], many studies have
unraveled the progressive incidence of IFN insensitivity and chronic inflammation and have been
reviewed elsewhere [40–42,69–71]. In addition, a pathological consequence from persistent IFN
and pro-inflammatory response, as well as the remarkable presence of auto-Abs, represent typical
pathological mechanisms underlying most autoimmune diseases, including diabetes, multiple sclerosis,
and systemic lupus erythematosus (SLE) [40–42,69–71]. The dysregulation of IFN and other immune
factors in the COVID-19 patients with pre-existing comorbidities could be further complicated by
the virus attacking endothelial cells to cause vasculitis, aneurysms, and coagulopathy, as well as
tissue damage in the kidney, heart, and even brain [72–75]. The dysregulation of the IFN response
can progressively result from the viral antagonism and virulence during viral replication (Figure 1).
Furthermore, the preexisting comorbidities, gender and age inclination, and, particularly, exacerbated
hyper inflammation associated with the IFN immunopathies and rigorous viral infection will undermine
the distinctness of immune and pathological responses and lead to a life-threatening situation or
death [10–12,61–63]. The inborn genetic and autoimmune deficiency of IFN response has been shown
in about 14% of the examined life-threatening COVID-19 patients [51,52] who may experience sudden
consequence even without a severe progression, thus further associating the dysfunction of IFN response
with severe and life-threatening COVID-19 [51,52]. Hence, the prophylactic or therapeutic effect of IFN
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trial regimens should be carefully designed based on the temporal characteristics and subtype specificity
of IFN responses during SARS-CoV-2 infection and the disease progression [25,49,50,53,54,76].
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Figure 2. Schematic of patient cohorts of SARS-CoV-2 infections based on the severity of COVID-19
and underlying IFN responses. e effective or dysregulated interferon (IFN) response underlies
the development of severe and life-threatening COVID-19. The dysregulation of IFN response
can progressively result from the viral antagonis /virulence, preexisting comorbidities, gender/age
inclination, and exacerbated hyper inflam ation, with the extremal genetic flaws impairing the IFN
signaling pathway. Hence, the prophylactic or therapeutic effect of IFN therapies should be designed
and more dependent on the spatiotemporal kinetics of IFN responses during SARS-CoV-2 infection
and the disease progression. In addition to its evolving antagonism to divert the host IFN response, the
high contagiousness of SARS-CoV-2 also comes from the efficient virus infection and spreading by the
non-hospitalized individuals who are asymptomatic or only have mild signs.
5. Conclusive Remarks: Precise IFN Response Kinetics and Application to COVID-19 Clinical Trials
Effective IFN response or IFN dysregulation constitutes a key determinant of COVID-19 prognosis,
which also highlights the potential of IFNs for therapeutic intervention [25]. Prophylactic administration
of IFNs at the early stage prior to pneumonia progression may antagonize the viral suppression on IFN
production and elicit an autonomous antiviral state in affected cells to block viral infection and COVID-19
pathogenesis. An early trial study (NCT04320238) showed that daily IFNα nasal drops enhanced
the protection of at-risk healthcare workers from COVID-19 over 28 days without noticeable adverse
effects [77]. However, the COVID-19 therapeutic effect of IFN treatments remains controversial, with
respect to particularly the timing of administration and the pre-existing medical condition according to
COVID-19 progression [25,78]. Interferon signaling has intricating crosstalk with multiple inflammatory
cytokines, including TNF-α, IL-6, because they intersect in using some common intracellular signaling
components [16,27]. In this context, the prophylactic effect of early IFN application may actually mitigate
the CRS through the antiviral and anti-inflammatory effect of some epithelial-specific IFN subtypes.
However, extensive validation of subtype-specific activity is warranted for better optimization of IFN’s
clinical uses [79–81]. By contrast, clinical trials of relevant IL-6, TNF, and JAK STAT inhibitors and
blocking antibodies are applied to the adverse side of dysregulated IFN response, which are devised to
mitigate the pathological IFN and pro-inflammatory response sustained in severe COVID-19 [79–81].
Recent studies, per significant association of life-threatening COVID-19 with inborn genetic flaws
and auto-Abs that block IFN response, genetically and epigenetically, reveal the critical role of IFN
dysregulation in severe COVID-19 [51,52]. In most other severe COVID-19 patients without genetic
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errors in IFN-relevant gene loci, IFN dysregulation is progressively worsened and associated with the
situation of pro-inflammation and immunopathy, which is prone to autoimmunity [41,61–63,82–84].
In addition, the high correlation of severe COVID-19 with seniority, males, and individuals with
pre-existing comorbidities will be plausibly explained by the coincidence of IFN dysfunction in these
listed situations, which have been reviewed elsewhere [41,82–86]. In addition, ACE2, a key enzyme of
RAAS and sneaked as a primary receptor by SARS-CoV-2 infection, has been recently identified as a
non-canonical ISG like IL-6 in response to IFN-induced epigenetic regulation [18,28–32]. Because the
expression and affinity of ACE2 to SARS-CoV-2 determine host susceptibility and cell tropism [28–32],
the dysregulated IFN response will further deteriorate the viral infection in multiple organs and
incapacitate a series of functions regulated through the RAAS axis [30,86]. This will certainly complicate
the understanding and application of IFNs, particularly for the treatment of severe COVID-19 [25,30,86].
All these call for a better understanding of the spatiotemporal characteristics and subtype-specificity of
IFN response to SARS-CoV-2 infections, which are warranted to devise IFN-related prophylactics and
therapies. It is noteworthy that all designed IFN therapies, which are based on normal IFN signaling,
will be not properly functional in individuals who have an inborn genetic or auto-immune deficiency
of the IFN system [52,53]. This will demand early diagnosis of this kind of genetic and auto-Ab errors
in potential and hospitalized patients who are irresponsive to IFN-based treatments [27,52,53].
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